Fas-mediated cholangiopathy in the murine model of graft versus host disease

Hepatology

Volumn 31, Issue 4, 2000, Pages 966-974

  Ueno, Yoshiyuki ^a   Ishii, Motoyasu ^a   Yahagi, Kaichiro ^a   Mano, Yutaka ^a   Kisara, Norihiro ^a   Nakamura, Norio ^b   Shimosegawa, Tooru ^a   Toyota, Takayoshi ^a   Nagata, Shigekazu ^c  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MOCHIDA PHARMACEUTICAL CO   (Japan)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BILE DUCT DISEASE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE ASSOCIATION; DOSE RESPONSE; GRAFT VERSUS HOST REACTION; IMMUNOCYTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034024669     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/he.2000.5764     Document Type: Article

References (34)

1. Krams SM, Martinez LA. Apoptosis as a mechanism of tissue injury in liver allograft rejection. Semin Liver Dis 1998;18:153-167.
2. Snover D. Problems in the interpretation of liver biopsies after liver transplantation. Am J Surg Pathol 1989;13:31-38.
3. Howell CD, Yoder T, Claman HN, Vierling JM. Hepatic homing of mononuclear inflammatory cells isolated during murine chronic graft-vs-host disease. J Immunol 1989;143:476-483.
4. Nagata S. Apoptosis: telling cells their time is up. Curr Biol 1996;6:1241-1243.
5. Fraser A, Evan G. A license to kill. Cell 1996;85:781-784.
6. Nagata S, Goldstein P. The Fas death factor. Science 1995;267:1449-1456.
7. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-1178.
8. Suda T, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 1994;179:873-879.
9. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nature Med 1997;3:409-413.
10. Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, Fusamoto H, et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. HEPATOLOGY 1994;19:1354-1359.
11. Cruickshank SM, Southgate J, Selby PJ, Trejdosiewicz LK. Expression and cytokine regulation of immune recognition elements by normal human biliary epithelial and established liver cell lines in vitro. J Hepatol 1998;29:550-558.
12. Faubion WA, Gores GJ. Death receprots in liver biology and pathology. HEPATOLOGY 1999;29:1-48.
13. Kuroki T, Seki S, Kawakita N, Nakatani K, Hisa T, Kitada T, Sakaguchi H. Expression of antigens related to apoptosis and cell proliferation in chronic nonsuppurative destructive cholangitis in primary biliary cirrhosis. Virchows Archiv 1996;429:119-129.
14. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806-809.
15. Howell CD, Li J, Roper E, Kotzin BL. Biased liver T cell receptor V beta repertoire in a murine graft-versus-host disease model. J Immunol 1995;155:2350-2358.
16. Yahagi K, Ishii M, Kobayashi K, Ueno Y, Mano Y, Niitsuma H, Igasashi T, et al. Primary, culture of cholangiocytes from normal mouse liver. In Vitro Cell Devel Biol 1998;34:512-514.
17. Chu JL, Drappa J, Parnassa A, Elkon KB. The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn. J Exp Med 1993;178:723-730.
18. Ueno Y, Phillips JO, Ludwig J, Lichtman SN, LaRusso NF. Development and characterization of a rodent model of immune-mediated cholangitis. Proc Natl Acad Sci U S A 1996;93:216-220.
19. Ueno Y, Ishii M, Takahashi S, Igarashi T, Toyota T, LaRusso NF. Different susceptibility of mice to immune-mediated cholangitis induced by immunization with carbonic anhydrase II. Lab Invest 1998;78:629-637.
20. Kraus MD, Shahsafaei A, Antin J, Odze RD. Relationship of Bcl-2 expression with apoptosis and proliferation in colonic graft versus host disease. Hum Pathol 1998;29:869-875.
21. Washington K, Bentley RC, Green A, Olson J, Treem WR, Krigman HR. Gastric graft-versus-host disease: a blinded histologic study. American Journal of Surgical Pathology 1997;21:1037-1046.
22. Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 1996;183:2645-2656.
23. Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J. Cytotoxic T cells deficient in both functional fas ligand and perform show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 1996;183:657-661.
24. Baker MB, Podack ER, Levy RB. Perform- and Fas-mediated cytotoxic pathways are not required for allogeneic resistance to bone marrow grafts in mice. Biol Blood Marrow Transplant 1995;1:69-73.
25. Ware CF, VanArsdale S, VanArsdale TL. Apoptosis mediated by the TNF-related cytokine and receptor families. J Cell Biochem 1996;60:47-55.
26. Yasoshima M, Kono N, Sugawara H, Katayanagi K, Harada K, Nakanuma Y. Increased expression of interleukin-6 and tumor necrosis factor-alpha in pathologic biliary epithelial cells: in situ and culture study. Lab Invest 1998;78:89-100.
27. Shustov A, Nguyen P, Finkelman F, Elkon KB, Via CS. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production. J Immunol 1998;161:2848-2855.
28. Hreha G, Jefferson DM, Yu C-H, Grubman SA, Alsabeh R, Geller SA, Vierling JM. Immortalized intrahepatic mouse biliary epithelial cells: Immunologic characterization and immunogenicity. HEPATOLOGY 1999;30:358-371.
29. Via CS, Nguyen P, Shustov A, Drappa J, Elkon KB. A major role for the Fas pathway in acute graft-versus-host disease. J Immunol 1996;157:5387-5393.
30. Nakamoto Y, Guidotti LG, Pasquetto V, Schreiber RD, Chisari FV. Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice. J Immunol 1997;158:5692-5697.
31. Nistico P, Tecce R, Giacomini P, Cavallari A, D'Agnano I, Fisher PB, Natali PG. Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells. Cancer Research 1990;50:7422-7429.
32. Miwa K, Hashimoto H, Yatomi T, Nakamura N, Nagata S, Suda T. Therapeutic effect of an anti-Fas ligand mAb on lethal graft-versus-host disease. Int Immunol 1999;11:925-931.
33. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991;324:667-674.
34. Schlitt HJ. Clinical and immunological aspects of liver allograft rejection. Transplant Proc 1996;28:514-516.